Incruse Ellipta (umeclidinium) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). The drug comes as a dry powder that you inhale. It’s typically used once per ...

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted from ...

Incruse Ellipta (umeclidinium) is a prescription drug used for treating chronic obstructive pulmonary disease (COPD). Incruse Ellipta can cause side effects that range from mild to serious. Examples ...

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment ...

Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma. Incruse® Ellipta® now available in the US for once-daily treatment for COPD. GlaxoSmithKline plc (LSE/NYSE: GSK) today ...

New Inhalers for Asthma, COPD Launched by GSK GlaxoSmithKline announced the launch of Arnuity Ellipta (fluticasone furoate inhalation powder) and Incruse Ellipta (umeclidinium bromide inhalation ...

MISSISSAUGA, ON, April 17, 2014 /CNW/ - GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada ...

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects, such as ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to INCRUSE ...